Home Contact us Site Map
 
 
 
May, 2008: Meiact® Launching symposia in Kuwait, Jordan and Libya with the attendance of the international speakers; Mr. Ko Kishimoto and Mr. Tanaka –from Meiji- Japan
May, 2008: Meiact® Launching symposia in Kuwait, Jordan and Libya with the attendance of the international speakers; Mr. Ko Kishimoto and Mr. Tanaka –from Meiji- Japan
Meiact® is a new under licensed molecule from Meiji- Japan, Cefditoren Pivoxil 400mg F.C. Tab., It is an advanced generation cephalosporin characterized by potent advanced gram-balanced spectrum with proven efficacy over the current 3rd - 2nd and 1st generation cephalosporins. The balanced spectrum, Beta lactamases stability, proven safety and high tolerability profile make Meiact® the physician’s 1st choice empirical treatment of respiratory tract infection in adults.



Return